Comparison of levofloxacin and garenoxacin for antibacterial prophylaxis during neutropenia

Ryoko Yamasaki, Junya Kanda, Yu Akahoshi, Hirofumi Nakano, Tomotaka Ugai, Hidenori Wada, Koji Kawamura, Yuko Ishihara, Kana Sakamoto, Miki Sato, Masahiro Ashizawa, Tomohito Machishima, Kiriko Terasako-Saito, Shun ichi Kimura, Misato Kikuchi, Hideki Nakasone, Rie Yamazaki, Shinichi Kako, Junji Nishida, Yoshinobu Kanda

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Levofloxacin (LVFX) is widely used for antibacterial prophylaxis during neutropenia. Garenoxacin (GRNX), which has been investigated in Japan, has stronger antibacterial activity than LVFX against gram-positive bacteria; however, no studies have compared the effectiveness of LVFX and GRNX. We retrospectively analyzed 42 patients with acute leukemia and 32 patients who underwent hematopoietic cell transplantation. Thirty-one patients before September 2009 received GRNX, and subsequent 43 patients received LVFX. We compared the cumulative incidences of positive blood and stool cultures. There was no significant difference in the incidence of bacteremia between the GRNX and LVFX groups. However, while gram-negative bacteria were detected in 80% of the patients with bacteremia in the GRNX group, they were detected in only 33% of the patients with bacteremia in the LVFX group. Patients in the GRNX group more frequently experienced positive stool cultures than those in the LVFX group, and this was confirmed by a multivariate analysis. Gram-negative bacteria accounted for 100 and 67% of the stool culture results in the GRNX and LVFX groups, respectively. While both fluoroquinolones may be appropriate antibacterial prophylactic agents for neutropenia patients with hematological malignancies, vigilance for gram-negative bacterial infections should be exercised when GRNX is used as prophylaxis.

Original languageEnglish
Pages (from-to)835-840
Number of pages6
JournalInternational Journal of Hematology
Volume105
Issue number6
DOIs
Publication statusPublished - 2017 Jun 1
Externally publishedYes

Fingerprint

Levofloxacin
Neutropenia
Bacteremia
Gram-Negative Bacteria
Gram-Negative Bacterial Infections
garenoxacin
Fluoroquinolones
Incidence
Cell Transplantation
Gram-Positive Bacteria
Hematologic Neoplasms
Japan
Leukemia
Multivariate Analysis
Anti-Bacterial Agents

Keywords

  • Antibacterial prophylaxis
  • Garenoxacin
  • Levofloxacin
  • Neutropenia

ASJC Scopus subject areas

  • Hematology

Cite this

Yamasaki, R., Kanda, J., Akahoshi, Y., Nakano, H., Ugai, T., Wada, H., ... Kanda, Y. (2017). Comparison of levofloxacin and garenoxacin for antibacterial prophylaxis during neutropenia. International Journal of Hematology, 105(6), 835-840. https://doi.org/10.1007/s12185-017-2188-2

Comparison of levofloxacin and garenoxacin for antibacterial prophylaxis during neutropenia. / Yamasaki, Ryoko; Kanda, Junya; Akahoshi, Yu; Nakano, Hirofumi; Ugai, Tomotaka; Wada, Hidenori; Kawamura, Koji; Ishihara, Yuko; Sakamoto, Kana; Sato, Miki; Ashizawa, Masahiro; Machishima, Tomohito; Terasako-Saito, Kiriko; Kimura, Shun ichi; Kikuchi, Misato; Nakasone, Hideki; Yamazaki, Rie; Kako, Shinichi; Nishida, Junji; Kanda, Yoshinobu.

In: International Journal of Hematology, Vol. 105, No. 6, 01.06.2017, p. 835-840.

Research output: Contribution to journalArticle

Yamasaki, R, Kanda, J, Akahoshi, Y, Nakano, H, Ugai, T, Wada, H, Kawamura, K, Ishihara, Y, Sakamoto, K, Sato, M, Ashizawa, M, Machishima, T, Terasako-Saito, K, Kimura, SI, Kikuchi, M, Nakasone, H, Yamazaki, R, Kako, S, Nishida, J & Kanda, Y 2017, 'Comparison of levofloxacin and garenoxacin for antibacterial prophylaxis during neutropenia', International Journal of Hematology, vol. 105, no. 6, pp. 835-840. https://doi.org/10.1007/s12185-017-2188-2
Yamasaki, Ryoko ; Kanda, Junya ; Akahoshi, Yu ; Nakano, Hirofumi ; Ugai, Tomotaka ; Wada, Hidenori ; Kawamura, Koji ; Ishihara, Yuko ; Sakamoto, Kana ; Sato, Miki ; Ashizawa, Masahiro ; Machishima, Tomohito ; Terasako-Saito, Kiriko ; Kimura, Shun ichi ; Kikuchi, Misato ; Nakasone, Hideki ; Yamazaki, Rie ; Kako, Shinichi ; Nishida, Junji ; Kanda, Yoshinobu. / Comparison of levofloxacin and garenoxacin for antibacterial prophylaxis during neutropenia. In: International Journal of Hematology. 2017 ; Vol. 105, No. 6. pp. 835-840.
@article{92ec3d27bb96453588799a9d4611fbeb,
title = "Comparison of levofloxacin and garenoxacin for antibacterial prophylaxis during neutropenia",
abstract = "Levofloxacin (LVFX) is widely used for antibacterial prophylaxis during neutropenia. Garenoxacin (GRNX), which has been investigated in Japan, has stronger antibacterial activity than LVFX against gram-positive bacteria; however, no studies have compared the effectiveness of LVFX and GRNX. We retrospectively analyzed 42 patients with acute leukemia and 32 patients who underwent hematopoietic cell transplantation. Thirty-one patients before September 2009 received GRNX, and subsequent 43 patients received LVFX. We compared the cumulative incidences of positive blood and stool cultures. There was no significant difference in the incidence of bacteremia between the GRNX and LVFX groups. However, while gram-negative bacteria were detected in 80{\%} of the patients with bacteremia in the GRNX group, they were detected in only 33{\%} of the patients with bacteremia in the LVFX group. Patients in the GRNX group more frequently experienced positive stool cultures than those in the LVFX group, and this was confirmed by a multivariate analysis. Gram-negative bacteria accounted for 100 and 67{\%} of the stool culture results in the GRNX and LVFX groups, respectively. While both fluoroquinolones may be appropriate antibacterial prophylactic agents for neutropenia patients with hematological malignancies, vigilance for gram-negative bacterial infections should be exercised when GRNX is used as prophylaxis.",
keywords = "Antibacterial prophylaxis, Garenoxacin, Levofloxacin, Neutropenia",
author = "Ryoko Yamasaki and Junya Kanda and Yu Akahoshi and Hirofumi Nakano and Tomotaka Ugai and Hidenori Wada and Koji Kawamura and Yuko Ishihara and Kana Sakamoto and Miki Sato and Masahiro Ashizawa and Tomohito Machishima and Kiriko Terasako-Saito and Kimura, {Shun ichi} and Misato Kikuchi and Hideki Nakasone and Rie Yamazaki and Shinichi Kako and Junji Nishida and Yoshinobu Kanda",
year = "2017",
month = "6",
day = "1",
doi = "10.1007/s12185-017-2188-2",
language = "English",
volume = "105",
pages = "835--840",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Comparison of levofloxacin and garenoxacin for antibacterial prophylaxis during neutropenia

AU - Yamasaki, Ryoko

AU - Kanda, Junya

AU - Akahoshi, Yu

AU - Nakano, Hirofumi

AU - Ugai, Tomotaka

AU - Wada, Hidenori

AU - Kawamura, Koji

AU - Ishihara, Yuko

AU - Sakamoto, Kana

AU - Sato, Miki

AU - Ashizawa, Masahiro

AU - Machishima, Tomohito

AU - Terasako-Saito, Kiriko

AU - Kimura, Shun ichi

AU - Kikuchi, Misato

AU - Nakasone, Hideki

AU - Yamazaki, Rie

AU - Kako, Shinichi

AU - Nishida, Junji

AU - Kanda, Yoshinobu

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Levofloxacin (LVFX) is widely used for antibacterial prophylaxis during neutropenia. Garenoxacin (GRNX), which has been investigated in Japan, has stronger antibacterial activity than LVFX against gram-positive bacteria; however, no studies have compared the effectiveness of LVFX and GRNX. We retrospectively analyzed 42 patients with acute leukemia and 32 patients who underwent hematopoietic cell transplantation. Thirty-one patients before September 2009 received GRNX, and subsequent 43 patients received LVFX. We compared the cumulative incidences of positive blood and stool cultures. There was no significant difference in the incidence of bacteremia between the GRNX and LVFX groups. However, while gram-negative bacteria were detected in 80% of the patients with bacteremia in the GRNX group, they were detected in only 33% of the patients with bacteremia in the LVFX group. Patients in the GRNX group more frequently experienced positive stool cultures than those in the LVFX group, and this was confirmed by a multivariate analysis. Gram-negative bacteria accounted for 100 and 67% of the stool culture results in the GRNX and LVFX groups, respectively. While both fluoroquinolones may be appropriate antibacterial prophylactic agents for neutropenia patients with hematological malignancies, vigilance for gram-negative bacterial infections should be exercised when GRNX is used as prophylaxis.

AB - Levofloxacin (LVFX) is widely used for antibacterial prophylaxis during neutropenia. Garenoxacin (GRNX), which has been investigated in Japan, has stronger antibacterial activity than LVFX against gram-positive bacteria; however, no studies have compared the effectiveness of LVFX and GRNX. We retrospectively analyzed 42 patients with acute leukemia and 32 patients who underwent hematopoietic cell transplantation. Thirty-one patients before September 2009 received GRNX, and subsequent 43 patients received LVFX. We compared the cumulative incidences of positive blood and stool cultures. There was no significant difference in the incidence of bacteremia between the GRNX and LVFX groups. However, while gram-negative bacteria were detected in 80% of the patients with bacteremia in the GRNX group, they were detected in only 33% of the patients with bacteremia in the LVFX group. Patients in the GRNX group more frequently experienced positive stool cultures than those in the LVFX group, and this was confirmed by a multivariate analysis. Gram-negative bacteria accounted for 100 and 67% of the stool culture results in the GRNX and LVFX groups, respectively. While both fluoroquinolones may be appropriate antibacterial prophylactic agents for neutropenia patients with hematological malignancies, vigilance for gram-negative bacterial infections should be exercised when GRNX is used as prophylaxis.

KW - Antibacterial prophylaxis

KW - Garenoxacin

KW - Levofloxacin

KW - Neutropenia

UR - http://www.scopus.com/inward/record.url?scp=85011634639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011634639&partnerID=8YFLogxK

U2 - 10.1007/s12185-017-2188-2

DO - 10.1007/s12185-017-2188-2

M3 - Article

C2 - 28168415

AN - SCOPUS:85011634639

VL - 105

SP - 835

EP - 840

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 6

ER -